# OnCo record pancreatic-undifferentiated-carcinoma-ogc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/pancreatic-undifferentiated-carcinoma-ogc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "pancreatic-undifferentiated-carcinoma-ogc" ;
  schema:name "Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells"@en ;
  schema:alternateName "Undifferentiated carcinoma with osteoclast-like giant cells (1.4 percent of resected pancreatic cancers; five-year survival 59 percent)"@en, "Osteoclastic giant cell tumour of the pancreas"@en, "UC-OGC"@en, "Undifferentiated carcinoma with osteoclastic giant cells"@en, "Giant cell carcinoma of the pancreas"@en ;
  schema:description "Undifferentiated carcinoma with osteoclast-like giant cells is a rare form of pancreatic cancer studded with large bone-eating-type cells that are not themselves cancerous. It grows as a big, well-circumscribed mass, often within a cyst, spreads to nerves and lymph nodes far less often than ordinary pancreatic cancer, and about six in ten patients are alive five years after surgery."@en ;
  schema:url <https://onco.cc/cancers/pancreatic-undifferentiated-carcinoma-ogc/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Giant-cell_tumor_of_bone> ;
  schema:citation <https://doi.org/10.1097/pas.0000000000000689>, <https://doi.org/10.1007/s00428-021-03021-9>, <https://doi.org/10.1111/his.13975> ;
  onco:tag "gi", "pancreatic", "subtype-page" ;
  onco:related <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/pancreatic-adenosquamous-carcinoma/>, <https://onco.cc/cancers/mcn-associated-carcinoma/>, <https://onco.cc/cancers/ipmn-associated-carcinoma/>, <https://onco.cc/cancers/undifferentiated-pleomorphic-sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/histopathology-ihc/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pancreatic-cancer-signalling/>, <https://onco.cc/pathways/emt/> ;
  onco:terms <https://onco.cc/terms/tumour-grade/>, <https://onco.cc/terms/whipple/>, <https://onco.cc/terms/resection-margins/> ;
  onco:standardOfCare <https://onco.cc/terms/whipple/>, <https://onco.cc/terms/distal-pancreatectomy/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/> .
